N/A
Manufactured by AiPing Pharmaceutical, Inc.
13,542 FDA adverse event reports analyzed
Last updated: 2026-04-14
METHIMAZOLE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by AiPing Pharmaceutical, Inc.. The most commonly reported adverse reactions for METHIMAZOLE include DRUG INEFFECTIVE, OFF LABEL USE, FATIGUE, HYPERTHYROIDISM, NAUSEA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for METHIMAZOLE.
Out of 7,409 classified reports for METHIMAZOLE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 13,542 FDA FAERS reports that mention METHIMAZOLE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, OFF LABEL USE, FATIGUE, HYPERTHYROIDISM, NAUSEA, DIARRHOEA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list AiPing Pharmaceutical, Inc. in connection with METHIMAZOLE. Always verify the specific product and NDC with your pharmacist.